Literature DB >> 2614685

Effect of propranolol on the myocardial contractility of normotensive and spontaneously hypertensive rabbits: relationship of pharmacokinetics and pharmacodynamics.

M Corbo1, P R Wang, J K Li, Y W Chien.   

Abstract

Myocardial contractility of normotensive and spontaneously hypertensive rabbits was determined following an iv bolus injection of propranolol HCl. Left ventricular pressure and dimension were used to calculate the contractility parameters of (dP/dt)max, maximum fiber shortening velocity (Vcf), and the slope of the end systolic pressure-end systolic volume line (ESP-ESV line). Hypertension was induced by a methoxamine HCl iv infusion which mimicked the cardiac effects seen in essential hypertension. Propranolol caused a significant decrease in all contractility parameters (p less than 0.05) within 15 min after administration, with a peak effect occurring after 30-35 mins. The pharmacokinetics and pharmacodynamics of propranolol were fit using Hill's equation in conjunction with the concentration of drug in the theoretical effect compartment. The normotensive group of rabbits had a calculated EC(50) of 12.7 ng/ml, while the hypertensive group had an EC(50) of 6.9 ng/ml, indicating that the hypertensive rabbits were much more sensitive to the propranolol than the normotensive group. In addition, the normotensive group of rabbits demonstrated a much different pharmacokinetic-pharmacodynamic relationship than that of the hypertensive group, indicating that the hypertensive state of the animal has a significant effect upon the concentration-effect relationship.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2614685     DOI: 10.1007/bf01071349

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  10 in total

1.  Abnormalities of left ventricular contraction induced by beta adrenergic blockade.

Authors:  R H Helfant; M V Herman
Journal:  Circulation       Date:  1971-05       Impact factor: 29.690

2.  Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers.

Authors:  A Wellstein; D Palm; G G Belz; H F Pitschner
Journal:  Arzneimittelforschung       Date:  1985

3.  Mechanism of antihypertensive action of ketanserin in man.

Authors:  M A Schalekamp; G J Wenting
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-29

Review 4.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

5.  Simultaneous pharmacokinetic and pharmacodynamic modeling.

Authors:  W A Colburn
Journal:  J Pharmacokinet Biopharm       Date:  1981-06

6.  A comparative study of nitroglycerin and propranolol.

Authors:  E Robin; C Cowan; P Puri; S Ganguly; E DeBoyrie; M Martinez; T Stock; R J Bing
Journal:  Circulation       Date:  1967-08       Impact factor: 29.690

7.  End-systolic pressure/volume ratio: a new index of ventricular contractility.

Authors:  K Sagawa; H Suga; A A Shoukas; K M Bakalar
Journal:  Am J Cardiol       Date:  1977-11       Impact factor: 2.778

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  Systolic pressure--diameter relations in the normal conscious dog.

Authors:  F Mahler; J W Covell; J Ross
Journal:  Cardiovasc Res       Date:  1975-07       Impact factor: 10.787

10.  Versatile isocratic high-performance liquid chromatographic assay for propranolol and its basic, neutral and acidic metabolites in biological fluids.

Authors:  E C Kwong; D D Shen
Journal:  J Chromatogr       Date:  1987-03-06
  10 in total
  1 in total

1.  Response surface method: a novel strategy to optimize iontophoretic transdermal delivery of thyrotropin-releasing hormone.

Authors:  Y Y Huang; S M Wu; C Y Wang
Journal:  Pharm Res       Date:  1996-04       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.